E-resources
Peer reviewed
-
Chia, Daryl K. A.; Sundar, Raghav; Kim, Guowei; Ang, Jia Jun; Lum, Jeffrey H. Y.; Nga, Min En; Goh, Giap Hean; Seet, Ju Ee; Chee, Cheng Ean; Tan, Hon Lyn; Ho, Jingshan; Ngoi, Natalie Y. L.; Lee, Matilda X. W.; Muthu, Vaishnavi; Chan, Gloria H. J.; Pang, Angela S. L.; Ang, Yvonne L. E.; Choo, Joan R. E.; Lim, Joline S. J.; Teh, Jun Liang; Lwin, Aung; Soon, Yuen; Shabbir, Asim; So, Jimmy B. Y.; Yong, Wei Peng
Annals of surgical oncology, 12/2022, Volume: 29, Issue: 13Journal Article
Background Adding intraperitoneal paclitaxel (IP-PTX) to paclitaxel/5-fluoropyrimidine has shown promising results in patients with gastric cancer peritoneal metastases (GCPM) but has not been studied with standard-of-care platinum/fluoropyrimidine combinations. Our goal to was evaluate IP-PTX with capecitabine/oxaliplatin (XELOX) in GCPM. Methods Forty-four patients with GCPM received IP PTX (40 mg/m 2 , Days 1, 8), oral capecitabine (1000 mg/m 2 twice daily, Days 1–14) and intravenous oxaliplatin (100 mg/m 2 , Day 1) in 21-day cycles. Patients with synchronous GCPM underwent conversion surgery if they had good response after chemotherapy, conversion to negative cytology, no extraperitoneal metastasis, and no peritoneal disease during surgery. The primary endpoint was overall survival and secondary endpoints were progression-free survival and safety. Outcomes from the trial were compared against a matched cohort of 39 GCPM patients who received systemic chemotherapy (SC) comprising platinum/fluoropyrimidine. Results The median OS for the IP and SC groups was 14.6 and 10.6 months (hazard ratio HR 0.44; 95% confidence interval CI, 0.26–0.74; p = 0.002). The median PFS for the IP and SC group was 9.5 and 4.4 months respectively (HR 0.39; 95% CI 0.25–0.66; p < 0.001). Patients in the SC group were younger (IP vs. SC, 61 vs. 56 years, p = 0.021) and had better performance status (ECOG 0, IP vs. SC, 47.7% vs. 76.9%, p = 0.007) compared with the IP cohort. In IP group, conversion surgery was performed in 36.1% (13/36) of patients, with a median OS of 24.2 (95% CI 13.1–35.3) months and 1-year OS of 84.6%. Conclusions IP PTX with XELOX is a promising treatment option for GCPM patients. In patients with good response, conversion surgery was feasible with favourable outcomes.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.